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Summary
Objective: Although biochemical studies have examined the synovial ﬂuid (SF) of patients with temporomandibular joint (TMJ) disorders
(TMDs), the details of the molecular mechanism of bone destruction and remodeling remain unknown. In this study, we induced and charac-
terized osteoclast-like cells from the SF of patients with TMD and investigated the participation of these cells in the pathogenesis of TMD.
Methods: We collected SF cells from patients with TMD after a pumping procedure, cultured osteoclast-like cells, and examined their char-
acteristics, including osteoclast markers and bone resorption activities. In addition, we obtained ﬁbroblastic cells from the SF of TMD patients
by continuous sub-culturing. Using these ﬁbroblastic cells, we examined ﬁbroblast markers using immunocytochemical staining and analyzed
the receptor activator of nuclear-factor-kB ligand (RANKL) mRNA levels. Detection of soluble form of RANKL (sRANKL) in the SF was mea-
sured by enzyme-linked immunosorbent assay (ELISA).
Results: Osteoclast-like cells were induced from the SF cells of patients with TMD by adding recombinant human (rh) macrophage colony
stimulating factor (M-CSF) and either 1,25-dihydroxy vitamin D3 [1,25(OH)2D3] or prostaglandin E2 (PGE2). These multinucleated giant cells
were positive for tartrate-resistant acid phosphatase (TRAP) and had the ability to absorb bone. The ﬁbroblastic cells from the SF of TMD
patients were positive for ﬁbroblast markers and RANKL mRNA was up-regulated. Detection of sRANKL in SF of patient group was signiﬁ-
cantly higher than control group.
Conclusion: The results suggest that the joint-inﬁltrating SF cells from TMD patients play important roles in the pathogenesis of these disor-
ders, which is characterized by progressive bone destruction or remodeling.
ª 2006 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.





Temporomandibular joint (TMJ) disorders (TMDs) represent
a cluster of joint and muscle disorders that are character-
ized by joint sound, pain, and dysfunction of the TMJ. Pre-
vious reports have suggested that variable degrees of
inﬂammation exist in certain TMDs1,2. Recent advances in
arthroscopy and the biochemical analysis of synovial ﬂuids
(SF) have provided new insights into the pathophysiological
nature of TMDs. Various proteinases3e6, neuropeptides7,
and inﬂammatory cytokines, which include interleukin (IL)-1,
IL-6, and tumor necrosis factor-a (TNF-a)8e13, have been
detected in the SF of TMD patients and have been as-
sociated with factors that inﬂuence bone destruction.
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Received 4 June 2005; revision accepted 1 August 2006.Osteoarthritis (OA), which is a major TMD with a complex
etiology, involves degenerative changes in the articular car-
tilage or subchondral bone that lead to loss of joint function.
Morphological abnormalities, such as ﬂattening, erosion,
sclerosis, and chondro-osteophytes, are observed on the
articular surface of the mandibular condyle in OA of the
TMJ14,15. Although biochemical studies have been per-
formed previously on the SF of TMD patients, little is known
about the molecular events that occur during the develop-
ment of TMDs, including the pathogenesis of OA.
On the other hand, several lines of evidence suggest an
association between osteoclast formation and bone de-
struction in arthritis. It has been widely accepted that oste-
oclasts play a pivotal role in joint destruction or bone
remodeling of multiple joints in rheumatoid arthritis (RA)
and OA, and signiﬁcant effort has gone into investigating
the precise mechanism underlying this phenomenon. Oste-
oclasts are multinucleated, bone-resorbing cells that are de-
rived from CD34-positive hematopoietic stem cells16e18.
The osteoclast progenitors are members of the monocyte/
macrophage lineage17, which differentiate to become the291
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osteoclasts17,19,20. Mature osteoclasts are generated by
the fusion of these mononuclear preosteoclasts, and their
differentiation occurs in microenvironments that are sup-
ported physiologically by osteoblasts or stromal cells in
the bone marrow17,21e23.
Recently, we reported that multinucleated bone-resorbing
osteoclast-like cells were generated from cells of the SF in
knee joints from RA and OA patients. We detected tartrate-
resistant acid phosphatase (TRAP)-positive mononuclear
cells, which differentiated into multinucleated bone-resorb-
ing giant cells, in the SF of patients with RA or OA24,25. Al-
though the presence of these bone-resorbing cells and their
participation in the destruction of RA and OA joints are well-
known phenomena, the details of bone destruction and re-
modeling in the TMJs of patients with TMD remain un-
known. In the present study, we collected and
characterized osteoclast-like cells from the SF of patients
with TMD. In addition, we obtained ﬁbroblastic cells from
the SF of TMD patients by continuous sub-culturing. Using
these ﬁbroblastic cells, we developed a co-culture system
of ﬁbroblastic cells and peripheral blood monocytes, which
we used to investigate whether ﬁbroblastic cells from the
SF are capable of supporting the differentiation of mono-
cytes into osteoclasts. Thus, we considered the participa-




SF samples were collected from 13 TMJs of 11 TMD pa-
tients. The control group consisted of SF samples from
seven TMJs of four volunteers who had no symptoms of
TMD. The patients consisted of 11 females with an average
age of 33.8 years (range 17e61 years), while the control
group consisted of two males and two females with an av-
erage age of 27.0 years (range 25e30 years). All of the
TMD patients had received 3 months of conservative treat-
ment without relief of symptoms prior to the intra-articular
pumping and lavage. The conservative treatment modalities
included medication (non-steroidal anti-inﬂammatory drugs
and muscle relaxants), use of a bite splint, and physical
therapy. The patients were given no medication for at least
2 weeks before the SF sampling was performed.
Full, informed consent for sample aspiration was ob-
tained from each patient, and all of the subsequent proce-
dures were approved by the ethics committee of Kyushu
Dental College.
COLLECTION OF SF SAMPLES AND CELLS
SF samples were collected from the TMJs of patients with
TMD as previously described12. Brieﬂy, after the pumping
procedure, by aspiration with a 22-gauge needle under
aseptic conditions, and then washing the superior joint
space with physiological saline. The mixture of SF and sa-
line was gently aspirated and re-injected a total of 10 times.
The SF sample was then collected. As a result, SF was di-
luted by saline, and viscosity of SF was not admitted. The
joint-inﬁltrating cells from the SF were collected by centrifu-
gation at 1900 g, the supernatant of SF was separated
and stored at 80C until assayed for enzyme-linked immu-
nosorbent assay (ELISA). Erythrocytes in SF were elimi-
nated by lysis with an ammonium chloride solution. The
nucleated cells were washed twice with Ca2þe andMg2þefree phosphate-buffered saline (PBS) and counted
using a hemocytometer. Dead cells were excluded by stain-
ing with trypan blue.
CULTURING OF CELLS FROM THE SF
The joint-inﬁltrating cells from the SF samples were cul-
tured in a-minimum essential medium (a-MEM; Gibco
BRL, Gaithersburg, MD) that contained 10% heat-inacti-
vated fetal calf serum (FCS; Gibco BRL) and 100 U/ml pen-
icillinestreptomycin (Gibco BRL). A total of 100,000 cells
were seeded onto 8-well chamber slides (Lab-Tek Chamber
Slide; Becton Dickinson, Franklin Lakes, NJ), and cultured
in the presence or absence of 20 ng/ml recombinant human
(rh) macrophage colony stimulating factor (M-CSF) (Pepro-
Teck EC, London, UK) and either 107 M 1,25-dihydroxy vi-
tamin D3 [1,25(OH)2D3] (Calbiochem, San Diego, CA) or
107 M prostaglandin E2 (PGE2) (Cayman Chemical, Ann
Arbor, MI). The cells were maintained at 37C in humidiﬁed
air that contained 5% CO2, and half of the medium was
changed every 3 days. After 4 weeks, all of the wells
were treated with trypsin/EDTA (Gibco BRL), and the ﬁbro-
blast-like cells were removed. The remaining adherent cells
were cytochemically stained. The ﬁbroblast-like cells which
of no stimulation re-plated, and half of the medium was
changed every 7 days. After four to ﬁve passages, these
cells were used for the subsequent experiments.
CYTOCHEMICAL STAINING
At the end of the culture period, the cells were stained for
TRAP using a kit (Sigma Chemical Co., St. Louis, MO), in
accordance with the manufacturer’s instructions. The cells
were also stained with MayeGrunwaldeGiemsa by incuba-
tion for 5 min with a 1:1 dilution of MayeGrunwald solution
(Merck, Darmstadt, Germany) followed by incubation for
10 min with a 1:20 dilution of Giemsa solution (Merck).
BONE RESORPTION ASSAYS
To determine the resorption activities of the TRAP-posi-
tive giant cells, 100,000 cells from the SF were cultured
on dentin slices in 8-well chamber slides. Each well was
ﬁlled with 0.3 ml a-MEM that contained 10% FCS, 107 M
1,25(OH)2D3, and 20 ng/ml rhM-CSF. After incubation for
4 weeks, the adherent cells on the dentin slices were re-
moved by brushing into distilled water, and the slices
were cleaned by ultrasonication. Resorption pits were
then detected by staining with horseradish peroxidase-con-
jugated wheat germ agglutinin (WGA)-lectin (Sigma), as de-
scribed previously26. Brieﬂy, the dentin slices were
incubated with 50 mg/ml horseradish peroxidase-conjugated
WGA-lectin in 0.1 M PBS overnight at room temperature.
After three washes, the peroxidase reaction was developed
for 30 min using 0.05 M Tris buffer (pH 7.6) that contained
0.02% 3,3-diaminobenzidine tetrahydrochloride (DAB; Do-
jindo Laboratories, Kumamoto, Japan) and 0.006% H2O2.
The dentin slices were mounted on aluminum stubs,
sputtered with gold, and examined under the Hitachi S-
4300 scanning electron microscope (Tokyo, Japan). As an
alternative method for the analysis of bone resorption, the
joint-inﬁltrating cells from the SF were cultured on calcium
phosphate-coated discs (Osteologic; Becton Dickinson) us-
ing the culture conditions described above. After 14 days of
incubation, the discs were washed in 6% NaClO and 5.2%
NaCl to remove the cells, dried, and examined by phase-
contrast microscopy.
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POLYMERASE CHAIN REACTION (RT-PCR)
After the ﬁbroblast-like cells had been subcultured four to
ﬁve times and treated with 107 M 1,25(OH)2D3 or 10
7 M
prostaglandin E2 (PGE2) for 24 h, the receptor activator of
nuclear-factor-kB ligand (RANKL) and glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) mRNA levels were
analyzed by RT-PCR. RNA was extracted from the cells us-
ing the Total RNA Extraction Miniprep System (Viogene
Co., Sunnyvale, CA), as directed by the manufacturer.
Brieﬂy, cDNA was synthesized from 2 mg of total RNA in
a 30-ml reaction mixture that contained 500 mM dNTPs,
20 U ribonuclease inhibitor (Promega, Madison, WI), and
200 U Superscript-a reverse transcriptase (Invitrogen Life
Technology, Carlsbad, CA). The reaction was initially car-
ried out for 7 min at 70C, then for 60 min at 45C, followed
by 10 min at 70C, with a ﬁnal step of cooling to 4C. The
PCR primer sequences were designed and their speciﬁc-
ities conﬁrmed using a BLAST search of the NLM non-re-
dundant nucleotide sequence database (National Library
of Medicine, Bethesda, MD). Each cycle consisted of dena-
turation and annealing steps, with a ﬁnal extension step
(72C for 9 min). The primers used for the ampliﬁcation of
RANKL were as follows: forward, 50-GCCTCATGGTTA
GATCTGGC-30; and reverse, 50-TGACCAATACTTGGT
GCTTCC-30. The reproducibility of the RT-PCR was con-
ﬁrmed by at least three replicates. Individual PCR reactions
were carried out using reverse-transcribed RNA, Taq poly-
merase buffer, and 1 ml each of the sense and antisense
primers, in a total volume of 20 ml. The PCR products
were electrophoresed in 2% agarose gels and visualized
with ethidium bromide.
IMMUNOCYTOCHEMICAL STAINING OF FIBROBLAST-LIKE
CELLS
The ﬁbroblast-like cells from the SF after subculture were
seeded at 2 104 cells per well onto 4-well Lab-Tek cham-
ber slides and allowed to attach and spread on the slides
for 48 h. The cells were cultured in a-MEM that was supple-
mentedwith 10%heat-inactivated FCS and 100 U/ml penicil-
linestreptomycin (Gibco BRL), and maintained at 37C in
humidiﬁed air that contained 5% CO2. After incubation, the
cultured medium was removed, and the cells ware washed
twice with PBS. The cells were ﬁxed in 4% PBS-buffered
paraformaldehyde for 10 min and then washed twice in PBS.
The immunostaining procedures were carried out at room
temperature using the DAKO LSAB kit (DAKO, Carpinteria,
CA) in accordance with the manufacturer’s instructions. The
ﬁbroblast-like cells were stained immunocytochemically
with anti-human prolyl 4-hydroxylase (DAKO), anti-human
vimentin (COSMO BIO Co., Ltd, Tokyo, Japan), anti-human
macrophage marker (YLEM, Roma, Italy), and anti-human
dendritic cell (Serotec Ltd, Oxford, UK) murine monoclonal
antibodies.
CO-CULTURE OF FIBROBLAST-LIKE CELLS AND PERIPHERAL
BLOOD MONOCYTES
The ﬁbroblast-like cells from the SF were subcultured in
a-MEM that was supplemented with 10% FCS. The cells
were seeded at 5 104 cells per well into 24-well multi-
well dishes and the cultures reached conﬂuence after
incubation for 3 days. Peripheral blood monocytes were col-
lected as plastic-adherent cells, as described previously16.
Brieﬂy, peripheral blood was obtained from healthy donors,
and mononuclear cells were separated by Ficoll-Hypaque(Pharmacia, Uppsala, Sweden) density-gradient (1077 g/
ml) centrifugation (30 min at 400 g) and suspended in me-
dium. The cell suspensions were placed into 6-well multi-
well dishes and incubated for 2 h at 37C in a humidiﬁed
5% CO2 atmosphere. Thereafter, the non-adherent cells
were removed by repeated washing and the adherent cells
were collected by vigorous pipetting. More than 98% of the
recovered adherent cells were monocytes, based on their
morphology and CD14 expression, as assessed by ﬂow cy-
tometry using FACScan (Becton Dickinson) (data not
shown) The isolated monocytes were added at 5 105 cells
per well to the ﬁbroblast-like cells in 24-well multi-well
dishes. The cells were co-cultured for 4 weeks in a-MEM
that contained 10% FCS in the presence of 20 ng/ml rhM-
CSF and either 107 M 1,25(OH)2D3 or 10
7 M PGE2. At
the end of this incubation period, all of the wells were
treated with trypsin/EDTA, and the ﬁbroblast-like cells
were removed. The remaining adherent cells were exam-
ined for the cytochemical and functional characteristics of
osteoclasts, as described above.
To evaluate the effect of osteoprotegerin (OPG) on this
co-culture system, rhOPG (PEPRO TECH EC Ltd, London,
UK) was added to the cultures at a concentration of 10 or
100 ng/ml throughout the culture period.
MEASUREMENT OF THE sRANKL CONTENT AND TOTAL
PROTEIN
Detection of soluble form of RANKL (sRANKL) was
measured by an ELISA using the speciﬁc antibodies
and ELISA ampliﬁcation system (Invitrogen Life Technol-
ogy, Carlsbad, CA). Ninety-six-well plates were coated
overnight at 4C with anti-human polyclonal RANKL anti-
body (1:300 dilution; Santa Cruz Biotechnology, CA). Un-
bound antibodies were washed away using 0.2% Tween
20 (Sigma) in 0.1 M PBS. Then, the plates were blocked
with 1% bovine serum albmin (BSA) in 0.1 M PBS for 1 h
at room temperature. After washing, the samples were
added and incubated for 1 h at room temperature. And af-
ter washing, the detecting biotinylated goat IgG anti-hu-
man RANKL antibody (1:300 dilution; Zymed
Laboratories, South San Francisco, CA) was added and
the plates were incubated for 1 h at 37C. Next, alkaline
phosphataseeavidin (Zymed Laboratories) was added
and incubated for 30 min at room temperature. Then sub-
strate was added and incubated for 15 min and stopped
with 0.3 M H2SO4. The optical density was measured at
495 nm using a micro plate reader (Bio-Rad, Herts,
UK). Protein assay was performed using bicinchoninic
acid (BCA) assay method (Pierce, Rockford, IL). Each de-
tectable sRANKL concentration (pg/ml) shown was calcu-
lated per 1 mg of SF total protein as previously
described12.
STATISTICAL ANALYSIS
The results are presented as the means SD. Statistical
analysis was performed using the non-parametric Manne
Whitney U test. P values of <0.05 were considered to be
statistically signiﬁcant.
Results
QUANTIFICATION OF JOINT-INFILTRATING CELLS IN THE SF
The joint-inﬁltrating cells in the SF were collected by la-
vage and counted. There was a signiﬁcant (P< 0.01)
294 H. Takano et al.: Osteoclast-like cells from TMJ synovial ﬂuidsFig. 1. Phase-contrast photomicrograph of TMJ SF cells cultured for 2 weeks (A) and 4 weeks (B) in the presence of 20 ng/ml rh M-CSF and
107 M 1,25(OH)2D3. After 4 weeks, the culture showed a predominance of ﬁbroblastic cells (B). Original magniﬁcation, 100.increase in the average number of cells in the SF of the pa-
tient group (14.6 10.8 104 cells), as compared to the SF
of the control group (0.8 0.1 104 cells). Furthermore
there was no signiﬁcant differences in the average percent-
age of viable cells in the SF of the patient group
(96.3 5.7%) as compared with the SF of control group
(98.6 2.4%).
DIFFERENTIATION OF CULTURED JOINT-INFILTRATING CELLS
INTO MULTINUCLEATED BONE-RESORBING GIANT CELLS
The joint-inﬁltrating cells from the SF of TMD patients
were cultured in the presence of 107 M 1,25(OH)2D3 or
107 M PGE2 and 20 ng/ml rhM-CSF for 4 weeks. After 2
weeks of incubation, the cells had increased in number. Un-
der light microscopy, large, spindle-shaped, adherent cells
that resembled ﬁbroblastic cells were observed [Fig. 1(a)].
After 4 weeks of incubation, the cell cultures had reached
conﬂuence, and ﬁbroblastic cells predominated [Fig. 1(B)].
Multinucleated giant cells were seen after removal of the
other cells by brief treatment with trypsin/EDTA. These
large monocyte- or macrophage-like cells were multinucle-
ated and positive for TRAP [Fig. 2(A and B)]. Although mul-
tinucleated giant cells could be derived from the SF cells
from most of the joints, they were not inducible from the
cells collected from three TMJs of the TMD patients or
from any of the TMJs of the control group. The numbers
of joint-inﬁltrating cells in these joints were lower than that
in other joints affected by TMD (data not shown).FORMATION OF RESORPTION PITS ON DENTIN SLICES AND
CALCIUM PHOSPHATE-COATED DISCS
Calcium resorption, which is a distinctive function of oste-
oclasts, was observed after incubation for 14 days of cal-
cium phosphate-coated discs (Osteologic) with cells from
the SF of the patients. Numerous resorption pits were ob-
served by phase-contrast microscopy. Giant cells were ob-
served near the resorption pits [Fig. 3(A)]. The resorption
pits were clearly visible after removal of the cells with
bleach [Fig. 3(B)]. Moreover, resorption pits were formed
on dentin slices that were incubated with cells from the
SF of TMD patients [Fig. 4(A and B)], and were clearly vis-
ible in scanning electron micrographs (SEMs) [Fig. 4(B)].
EXPRESSION OF RANKL MRNA AFTER TREATMENT WITH
1,25(OH)2D3 OR PGE2
After sub-culturing, the ﬁbroblast-like cells from the SF of
the TMD patients were treated with 107 M 1,25(OH)2D3 or
107 M PGE2, to clarify the effects of stimulation on RANKL
expression. RANKL mRNA was up-regulated after 24 h of
stimulation with either agent (Fig. 5).
CELL SURFACE MARKERS OF THE FIBROBLAST-LIKE CELLS
All of the ﬁbroblast-like cells were positive for prolyl 4-hy-
droxylase [Fig. 6(A)] and vimentin [Fig. 6(B)], which are ﬁ-
broblast markers. In contrast, the cells stained negativeFig. 2. May-GrunwaldeGiemsa staining (A) and TRAP (B) of multinucleated giant cells after removal of the ﬁbroblastic cells. The cells induced
in this culture system were multinucleated and TRAP-positive. Original magniﬁcation, 200.
295Osteoarthritis and Cartilage Vol. 15, No. 3Fig. 3. Examination of resorption areas formed by multinucleated bone-resorbing giant cells on Osteologic discs, as seen by phase-contrast
microscopy (A, B, black arrows). Giant cells were present near the pits (A, white arrows). Original magniﬁcation, 200.for the macrophage marker and dendritic cell marker
[Fig. 6(C and D)]. No immunostaining was observed for con-
trol specimens that were incubated with the secondary an-
tibody alone (data not shown).
FORMATION OF MULTINUCLEATED BONE-RESORBING GIANT
CELLS BY CO-CULTURE OF FIBROBLAST-LIKE CELLS AND
PERIPHERAL BLOOD MONOCYTES
After the ﬁbroblast-like cells from TMD SF were co-cul-
tured with peripheral blood monocytes in the presence of
20 ng/ml rhM-CSF and either 107 M 1,25(OH)2D3 or
107 M PGE2 for 4 weeks, numerous TRAP-positive multi-
nucleated cells were observed [Fig. 7(A)]. However, in
cultures of peripheral blood monocytes alone, no multinu-
cleated cells [Fig. 7(B)] were detected following stimulation
with either 107 M 1,25(OH)2D3 or 10
7 M PGE2. The mul-
tinucleated cells formed in the co-cultures displayed osteo-
clastic characteristics.
EFFECT OF OPG ON OSTEOCLASTOGENESIS IN CO-CULTURE
OF FIBROBLAST-LIKE CELLS AND PERIPHERAL BLOOD
MONOCYTES
We investigated the effect of OPG on co-culture of ﬁbro-
blast-like cells and peripheral blood monocytes in the pres-
ence of 20 ng/ml rhM-CSF and 107 M 1,25(OH)2D3 for 3
weeks. TRAP-positive multinucleated giant cell formationwas signiﬁcantly inhibited by OPG (10 ng/ml, 100 ng/ml) in
this culture system [Fig. 8].
DETECTION OF THE sRANKL CONTENT IN SF
Using an ELISA, we detected sRANKL in both groups of
SF. Each detectable sRANKL concentration (pg/ml) shown
was calculated per 1 mg of SF total protein. The levels of
sRANKL in the SF of the patient group were signiﬁcantly
higher than the control group [Fig. 9].
Discussion
In this study, we collected joint-inﬁltrating cells from the
SF of the TMJs of patients with TMD and demonstrated
that these cells could be induced to differentiate into
TRAP-positive multinucleated bone-resorbing giant cells.
To the best of our knowledge, this is the ﬁrst study to in-
vestigate the molecular and cellular characteristics of
joint-inﬁltrating cells from the SF of TMJs. Although the
development of multinucleated giant cells was induced
from SF cells isolated from most of the joints, we could
not induce multinucleated giant cells from cells collected
from three TMJs of patients with TMD or from any of
the TMJs of the control group. The numbers of joint-inﬁl-
trating cells were lower in these joints than in other joints
affected by TMD, and these cells did not proliferate in
culture.Fig. 4. Examination of the resorption pits formed by multinucleated bone-resorbing giant cells on dentin slices. Lectin staining of lacunar
resorption of dentin slices on which multinucleated bone-resorbing giant cells were incubated (A). SEM (B). Bar¼ 50 mm in (A); 20 mm in (B).
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lead to an increase in vascular permeability, resulting in
the exudation of white blood cells, as well as inﬂammatory
mediators and various proteins into the joint spaces of the
TMJs. Clinically, these inﬂammatory changes result in
pain, soft tissue swelling, crepitus, and disability27. The ef-
fective vascular permeability across the bloodesynovial
barrier is a key factor in controlling SF volume and joint ef-
fusions. The hydraulic permeability of the synovium in-
creases at pathological intra-articular pressures, which is
a phenomenon of potential importance for effusion kinet-
ics28. In addition, the average number of joint-inﬁltrating
GAPDH
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Fig. 5. The stimulation of ﬁbroblastic cells from the SF with 107 M
1,25(OH)2D3 or 10
7 M PGE2 increased the expression of RANKL
mRNA (341 bp PCR product), as shown by RT-PCR. Lane 1, con-
trol (no stimulation); Lane 2, 107 M 1,25(OH)2D3; Lane 3, 10
8 M
1,25(OH)2D3; Lane 4, 10
7 M PGE2; Lane 5, 10
8 M PGE2.cells in the SF of the TMD patient group was signiﬁcantly
higher than that in the SF of the control group in this study.
These results suggest that the vascular permeability across
the bloodesynovial barrier of the TMJ is increased by in-
ﬂammation in TMD patients, with consequent increased ex-
travasation of white blood cells into the joint space.
Therefore, the SF of the TMJ of TMD patients may contain
more cells that have the capacity to differentiate into
preosteoclasts.
Recently, we reported that multinucleated bone-resorbing
osteoclast-like cells could be generated from peripheral
monocytes that differentiated into TRAP-positive mononu-
clear cells when induced by RA nurse-like cells24. In addi-
tion, it appears that certain cytokines in the SF of RA
patients are responsible for osteoclast-like cell formation.
Furthermore, we detected TRAP-positive mononuclear
cells, which differentiated into multinucleated bone-resorb-
ing giant cells, in the SF of patients with RA and OA25.
Quinn and Bazan were the ﬁrst to identify the presence of
PGE2 in the SF of inﬂamed, dysfunctional TMJs and to
show a signiﬁcant correlation with the level of acute synovi-
tis, which was assessed arthroscopically1. Numerous
subsequent studies have identiﬁed additional pro-inﬂamma-
tory cytokines, such as IL-1b, IL-6, and TNF-a3,9,10,12. The
pro-inﬂammatory cytokines (PGs, ILs, and TNF-a) are po-
tential regulators of osteoclastogenesis. Kotake et al.
have demonstrated that high levels of IL-6, soluble IL-6 re-
ceptor, and IL-17 in the SF of patients with RA appear to en-
hance osteoclastogenesis and promote joint29,30.
Kobayashi et al. have demonstrated that TNF-a stimulates
osteoclast differentiation in the presence of M-CSF in
mice and humans31. These combined ﬁndings suggestFig. 6. Immunocytochemical examination of ﬁbroblast-like cells from the SF of patients with TMD. All of the ﬁbroblast-like cells were positive for
prolyl 4-hydroxylase (A) and vimentin (B). Macrophage marker (C) and dendritic cell marker (D) showed negative staining. Original magniﬁ-
cation, 200.
297Osteoarthritis and Cartilage Vol. 15, No. 3Fig. 7. Examination of capability of supporting osteoclast formation on ﬁbroblast-like cells from the SF of patients with TMD in co-cultured with
peripheral blood monocyte. Numerous TRAP-positive multinucleated cells were appeared in co-culture of ﬁbroblast-like cells and peripheral
blood monocyte (A). Culture of only peripheral blood monocytes under the same condition, there were only a few two nuclei-cells (B).that the microenvironment of the joint space offers favorable
conditions for the differentiation of precursors to osteoclasts
when the production of inﬂammatory cytokines is increased
during TMD.
More recently, the molecular determinants of osteoclasto-
genesis have been identiﬁed; RANKL and M-CSF are indis-
pensable factors for osteoclastogenesis and are produced
by osteoblasts and bone marrow stromal cells32e35. RANKL
has been reported as a potent inducer of osteoclast devel-
opment from monocytes and is a key molecule in osteoclas-
togenesis36,37. Shigeyama et al. have recently reported that
synovial ﬁbroblasts in RA patients may promote osteoclas-
togenesis by expressing RANKL38. In the present study,
RANKL mRNA expression was increased by treatment of
adherent ﬁbroblast-like cells with 1,25(OH)2D3 or PGE2. In
addition, when OPG was added to co-culture of ﬁbroblast-
like cells and peripheral blood monocytes, osteoclastogen-
esis was inhibited in a dose dependent manner. The effect






























































































Fig. 8. Effect of OPG on osteoclastogenesis in co-culture of ﬁbro-
blast-like cells and peripheral blood monocytes. Inhibitory effects
of TRAP-positive multinucleated giant cells formation in response
to 10 ng/ml and 100 ng/ml of OPG in this culture system. Each
value represents meanSD. *P< 0.05 vs absence of OPG.was similar to that observed in co-culture of RA synovial ﬁ-
broblasts with peripheral blood mononuclear cells39. These
results reveal that these populations contain stromal cells,
and RANKL expressed on these ﬁbroblast-like cells may
support osteoclast differentiation of peripheral blood mono-
nuclear cells. Furthermore, sRANKL was detected in both
groups of SF. The levels of sRANKL in SF of the patient
group were signiﬁcantly higher than control group. It is
also suggested that sRANKL in the SF of TMD patients
may have activated osteoclastogenesis in TMJs.
In order to identify the inﬂuence of synovial ﬁbroblastic
cells on osteoclast formation in our culture system, ﬁbro-
blast-like cells were co-cultured with peripheral monocytes
in the presence of 1,25(OH)2D3 or PGE2. The results indi-
cate that ﬁbroblast-like cells from the SF of patients with
TMD have the property of stromal cells, i.e., that of support-
ing differentiation of SF monocytes/macrophages into oste-
oclasts. The ﬁbroblast-like cells in the SF of TMD patients
were positive for ﬁbroblast cell markers, such as prolyl 4-hy-
droxylase and vimentin, in immunocytostaining experi-
ments. In contrast, these cells were negative for
macrophage and dendritic cell markers. These results sug-
gest that ﬁbroblast-like cells obtained from the SF of TMD
patients by culturing are predominantly type B ﬁbroblast-





































Fig. 9. ELISA for sRANKL in SF. Each detectable sRANKL concen-
tration (pg/ml) shown was calculated per 1 mg of SF total protein.
Each value represents meanSD. n¼ 5; *P< 0.05 vs control.
298 H. Takano et al.: Osteoclast-like cells from TMJ synovial ﬂuidsAlthough the development of multinucleated giant cells
could be induced from the SF cells of most of the TMD pa-
tients, we were unable to derive giant cells from three TMJs
of the TMD patients or from any of the TMJs of the control
group. The numbers of joint-inﬁltrating cells were lower in
these joints than in other joints affected by TMD (data not
shown), which suggests that osteoclast induction may be
dependent upon the number of joint-inﬁltrating cells and/or
the grade of inﬂammation.
In conclusion, joint-inﬁltrating cells from the SF of TMD
patients may play important roles in the pathogenesis of
these disorders, which are characterized by progressive
bone destruction or remodeling, as well as in the enhanced
function of hematopoietic cells, such as preosteoclast-like
cells. These ﬁndings may shed light on the molecular mech-
anisms of bone resorption or remodeling in the pathophys-
iology of TMJ. Assuming that the formation of these cells
can be controlled, treatment modalities for TMJ diseases
could be modiﬁed drastically. However, further studies
concerning the characterization of these osteoclastic cells
are required to clarify the roles of these cells in TMD
pathogenesis.
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